Luiz Vinicius da Silva Correa

Luiz Vinicius da Silva Correa

Auto-generated profile, based on publicly available information

Luiz Vinicius da Silva Correa

Department of Neuroscience University of São Paulo Ribeirão Preto Brazil

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2022 in medRxiv
Verified
Preprint
Open access
PDF file
RTRodrigo Thomasi
Rodrigo Thomasi
TCThais da Silva Correa
Thais da Silva Correa
DCDalise Silva Do Carmo
Dalise Silva Do Carmo
DRDéborah Fernandes Rodrigues
Déborah Fernandes Rodrigues
LCLuiz Vinicius da Silva Correa
Luiz Vinicius da Silva Correa
ALEXSANDRO SOBREIRA GALDINOALEXSANDRO SOBREIRA GALDINO
ALEXSANDRO SOBREIRA GALDINO
Background Monkeypox is a global public health issue caused by the monkeypox virus (MPXV), a virus belonging to the Orthopoxvirus genus. As of October 28 2022, a total of 77,115 laboratory-confirmed cases and 3,610 probable cases, including 36 deaths, were reported, with 9,070 cases reported in Brazil, the second most affected country. The need to develop national technologies for the rapid diagnosis of emerging diseases for mass testing of the population is evident, as observed in the current SARS-CoV-2 pandemic. With that in mind, this article provides an overview of current methods, techniques, and their applications in the molecular detection of monkeypox. Methods The relevant documents or papers covered in this study were selected by a search in international bibliographic databases. The search terms used in the databases were aimed at summarizing existing knowledge on molecular diagnostic methods, such as: monkeypox; MPX, MPXV, qPCR, PCR, PCR-ELISA, and Diagnosis and Detection searched separately or together using the Boolean operator “AND” either in the title or The searches took place in September 2022, and the corresponding articles were selected between 2012 and 2022. Results We found 256 documents in total and twelve studies addressing the molecular diagnosis of monkeypox were classified as possible sources for this review. Conclusion This paper presents new perspectives and an overview of current methods, technologies, and applications in the molecular diagnosis of monkeypox. It is evident there is a pressing need to develop national technologies for the rapid diagnosis of emerging diseases for mass testing of the population. It is extremely important to have national detection kits with greater diagnostic capacity to assist in developing effective public policies in countries affected by this disease.

27 October 2026 in Journal of Neural Transmission
Verified
Journal Article
Open access
PDF file
BSBruno Lopes Santos-Lobato
Bruno Lopes Santos-Lobato
TMTatiane Piedade de Souza Machado
Tatiane Piedade de Souza Machado
LCLuiz Vinicius Silva Correa
Luiz Vinicius Silva Correa
MGMargarete Zanardo Gomes
Margarete Zanardo Gomes
EDElaine Del-Bel
Elaine Del-Bel
VTVitor Tumas
Vitor Tumas
Levodopa-induced dyskinesia (LID) remains a major limitation of long-term dopaminergic therapy in Parkinson’s disease (PD). Although LID is classically attributed to maladaptive corticostriatal plasticity driven by pulsatile dopaminergic stimulation in the dopamine-denervated striatum, accumulating evidence indicates that chronic neuroinflammation may lower the threshold for LID development and expression. Here, we synthesize preclinical, human biomarkers, neuroimaging, and genetic findings that support neuroinflammation as a mechanistic bridge between cellular stress and circuit-level maladaptation. In animal models, pharmacological modulation of inflammation-linked pathways, particularly nitrergic signaling, antibiotic repurposing, and cannabinoid-based strategies, attenuates abnormal involuntary movements and reduces striatal glial reactivity, implicating an inflammation–plasticity coupling in LID. In humans, post-mortem studies implicate regionally constrained mitochondrial DNA abnormalities and lipid dysregulation in the striatum, while biofluid metabolomics supports altered nitric oxide generation and lipid pathways associated with LID severity. Neuroimaging studies reveal markers consistent with oxidative stress and neurovascular dysfunction, and genetic studies link LID risk to variants in genes involved in lysosomal function, mitochondrial homeostasis, and inflammatory transcriptional programs. Integrated with the classic mechanisms of LID pathophysiology, we propose a conceptual model organized around three interrelated dimensions: (i) the topographical distribution of neuroinflammatory changes, particularly within the striatum; (ii) the interaction of neuroinflammation with mitochondrial dysfunction and lipid dysregulation; and (iii) the modifying influence of genetic susceptibility. This model motivates biomarker-guided, randomized trials targeting specific inflammatory nodes to prevent or mitigate LID.

25 May 2026 in Movement Disorders Clinical Practice
Verified
Journal Article
Open access
LCLuiz Vinicius Silva Correa
Luiz Vinicius Silva Correa
ANAlexandre Martins Do Nascimento
Alexandre Martins Do Nascimento
BSBruno Lopes Santos-Lobato
Bruno Lopes Santos-Lobato
HCHenry Mauricio Chaparro‐Solano
Henry Mauricio Chaparro‐Solano
IMIgnacio Fernandez Mata
Ignacio Fernandez Mata
VTVitor Tumas
Vitor Tumas
Background: Levodopa‐induced dyskinesia (LID) is a complication of Parkinson's disease (PD) treatment. While the placebo effect is a known component in PD clinical trials, its specific magnitude in the context of LID is not well characterized. Objective: To quantify the magnitude of the placebo response in LID trials and to identify potential moderators of this effect. Methods: We conducted a systematic review and meta‐analysis of double‐blind, placebo‐controlled trials in patients with PD and LID. The primary outcome was the change in dyskinesia severity in the placebo arm, pooled using random‐effects model. Results: Thirty one publications, comprising 1329 patients, were included. Data were stratified by reporting methodology: 16 studies provided primary LS mean change data, 11 provided simple change and the remaining studies contributing solely to subgroup analyses. The primary meta‐analysis, revealed a statistically significant placebo response of moderate magnitude (pooled SMD = −0.48, p < 0.0001), with significant heterogeneity ( I 2 = 47.6%). Subgroup analyses showed this corresponded to clinically measurable improvements, including a mean reduction of −6.78 points on the UDysRS and an increase of +1.27 h in “Good On Time.” Meta‐regression identified that a larger placebo effect was significantly associated with older patient age ( p = 0.014), a higher proportion of female participants ( p = 0.016), and shorter study duration ( p = 0.006). Conclusion: The placebo response in LID is a consistent, clinically relevant phenomenon modulated by patient demographics and trial duration. Quantifying this response is essential for design and accurate interpretation of future trials.